www.archive-us-2014.com » US » B » BIOARRAY

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".

    Archived pages: 20 . Archive date: 2014-10.

  • Title: Bioarray Home
    Descriptive info: .. HOME.. OUR TECHNOLOGY.. NEWS.. ABOUT US.. CONTACT.. Because.. breast cancer.. affects all of us.. Tweets by @BIOARRAYMDx.. Fighting breast cancer.. with a new generation of diagnostic tests.. BIOARRAY.. tests.. will provide.. patients and their doctors.. with information they need to make informed and personalized decisions about breast cancer treatment.. Recent news.. September 13, 2013 ----.. BIOARRAY is 1 out of 800 companies working in biosciences in Connecticut.. (.. Press release.. ).. Bioarray's open house celebration.. We  ...   May 20, 2013 ----.. The Avon Foundation, Connecticut Innovations, and private angel investors award a total of $400,000 to BIOARRAY enabling development of lead diagnostic test.. March 30, 2013 ----.. BIOARRAY announces new board member elected March 2013.. December 6, 2012 ----.. Progress report presented at the I-SPY 1 trial luncheon at the San Antonio Breast Cancer Symposium 2012.. more BIOARRAY NEWS.. Home.. Our Technology.. News.. About us.. Contact.. © Bioarray Therapeutics, Inc.. All rights reserved.. 2013..

    Original link path: /
    Open archive

  • Title: Bioarray Technology
    Descriptive info: Breast Cancer Response Prediction test.. BIOARRAY's lead product will be a quantitative in-vitro diagnostic test performed in a CLIA-certified laboratory using a gene expression profile to assess a breast cancer patient’s likelihood to respond to each of several standard-of-care pre-surgery (neoadjuvant) taxane-based chemotherapy options.. The readout, encompassing quantitative probability score, will provide accurate, personalized information that can help doctors and patients determine the best therapeutic course for each patient.. The target patients who will be offered the test are breast cancer patients with stage I-III disease, independent of lymph node status.. The patent-pending test measures the RNA expression levels of multiple markers (genes) in formalin-fixed, paraffin-embedded breast cancer tumor samples (collected under routine, standard of care practices) and employs the company's proprietary algorithms to produce a quantitative response score predicting the patient's response to chemotherapy  ...   chemotherapy to choose will be empowered by BIOARRAY’s test results.. They will be able to make more informed decisions by accessing the test's accurate information about the probability of response to treatment before the chemotherapy is given.. The potential impact of making the correct therapy choice include reductions in ineffective chemotherapy and repeat surgeries, reduction in radical surgery, decreased suffering, and lower economic costs.. 12-6-2012 BIOARRAY reported results of 147 patients with stage II-III breast cancer in the NCI-sponsored multicenter prospective study, I-SPY 1 trial.. The results showed that BIOARRAY’s markers predicted patient response to pre-surgery taxane-based chemotherapy with excellent performance (ROC AUC>0.. 8).. While further validation is yet to be achieved, these markers hold the promise to provide patients early in the care process with accurate and personalized information to predict response to chemotherapy..

    Original link path: /products.html
    Open archive

  • Title: Bioarray News
    Descriptive info: September 13, 2013 ----.. This is an outstanding moment for biosciences in Connecticut with Gov.. Malloy commitment of 200 million dollars to genomic research and personalized medicine.. This funding will foster even further the growth of the industry in the State which already counts with over 800 companies doing work connected to bioscience research.. “We are talking about an industry that is growing rapidly at 11% per year internationally” says Gov.. Malloy.. May 20, 2013 ----.. I wanted to thank those of you attending (especially from out of.. State!) and hope we made your time worthwhile.. For those of you who could not attend, I.. wanted to let you know how it went.. BIOARRAY’s team felt privileged to have the participation.. of many distinguished guests and we hope we can give back as much help as we are receiving.. New funding for breast cancer diagnostic.. March 30, 2013 ----.. BIOARRAY Therapeutics Inc.. (BIOARRAY) is pleased to welcome Una S.. Ryan O.. B.. E.. , Ph.. D.. , D.. Sc.. as the new Board Member electedon March 1, 2013.. As a Board Member, Dr.. Ryan will work together with BIOARRAY’s Board of Directors, Advisors and Team members to care for BIOARRAY’s mission of developing novel technology for effective treatment of cancer patients sooner.. As Managing Director at Golden Seeds (Silicon Valley), an angel investing group focused on women-led companies, and member of Astia Angel, a group of active and experienced angel investors, Dr.. Ryan is fostering the mission of investing in women-led ventures while targeting above-market investment returns.. Dr.. Ryan is the former President and CEO of Diagnostics For All (DFA), a non-profit organization developing inexpensive diagnostics for global health and agriculture.. Prior to that Dr.. Ryan held the President and CEO of AVANT Immunotherapeutics, Inc, (NASDAQ) a company developing vaccines and immunotherapeutics for cancer, travelers, food safety, and global health.. Learn more about Dr.. Ryan:.. www.. linkedin.. com/pub/una-ryan/10/207/a77.. December 6, 2012 ---- BIOARRAY reported results.. of 147  ...   plans.. The 2012 Connecticut Innovation Summit winners:.. 1.. Most Promising Technology Product of the Year - Emme E2MS LLC, Bristol.. 2.. Most Promising Software Product of the Year - eBrevia, LLC, Stamford.. 3.. Most Promising New Internet/New Media Company of the Year - Applivate LLC, New Haven.. 4.. Most Promising Life Sciences Product of the Year - BIOARRAY Therapeutics, Inc, Farmington.. 5.. Most Promising New Green Tech Product of the Year - RPM Sustainable Technologies, Inc, Guilford.. December 5, 2011 ----.. BIOARRAY CEO Marcia Fournier is Brazil expert on trade mission with Govenor Patrick (.. Boston Business Journal.. November 16, 2011.. ----.. BIOARRAY Founder CEO invited to join Massachusetts Govenor Patrick on an innovation and economy mission to Brazil.. October 24, 2011.. BIOARRAY is Silver Winner of MassChallenge.. September 23, 2011 ----.. BIOARRAY participates in the 2011 Mass Challenge Show Case.. More info and photos.. June 3, 2011 ----.. B.. IOARRAY publishes results for Chemotherapy Response Prediction Test in Journal of Clinical Oncology.. (Abstract).. May 24, 2011.. BIOARRAY selected as one of 125 MassChallenge finalists.. May 10, 2011.. BIOARRAY featured in.. Startup Watch: Five You Should Follow.. at Mass High Tech.. April 28, 2011 ----.. BIOARRAY presents and participates in panel at.. HBA Boston.. event – Innovation in the Age of Collaboration, Reconstructing the Value Chain.. April 6, 2011 ----.. BIOARRAY presents results for its Chemotherapy Response Prediction Test at the 2011.. AACR.. Conference, Orlando FL.. (Poster.. July 1, 2010 ----.. BIOARRAY publishes in Cancer Research calling for more research on biomarkers for early cancer detection.. (Article).. June 3, 2010 ----.. BIOARRAY presents preclinical data on its Chemotherapy Prediction Test at the.. 2010 American Society of Clinical Oncology (ASCO) Conference.. (Poster).. April 19, 2010 ----.. BIOARRAY presents preclinical data showing that its Chemotherapy Prediction Test is accurate in all breast cancer subtypes.. 2010.. Conference, Washington DC.. Abstract.. ) (.. Poster.. March 19, 2010 ----.. BIOARRAY selected as semi-finalist in 2010 North of Boston Business Plan Competition.. more..

    Original link path: /news.html
    Open archive

  • Title: Bioarray What we do
    Descriptive info: Recipient of research grant, 2013.. Recipient pre-seed fund, 2013.. Nominated Most Promising Life Science Product in 2012.. Silver Winner in 2011 (ranking in the top 26 out of 700 companies).. Sponsored company, 2011.. Company.. Team.. BIOARRAY's Therapeutics, Inc.. (BIOARRAY) is a privately held start up biotechnology company founded in 2009 in Boston, MA.. BIOARRAY.. is developing proprietary predictive diagnostic tests, based on cancer genes (markers), to choose to the most efficacious treatment for cancer patients beforehand, rather than the trial and error approach currently used..

    Original link path: /aboutus.html
    Open archive

  • Title: Bioarray Contact us
    Descriptive info: Bioarray Headquarters.. Technology Incubation Program University of Connecticut Cell and Genome Sciences Bldg.. 400 Farmington Ave.. Call Box 907 Farmington, CT 06032.. Boston Office.. Venture Development Center (VDC) University of Massachusetts Wheatley Hall, Third Floor.. 100 Morrissey Blvd.. Boston, MA 02125.. Directions:.. http://www.. umb.. edu/vdc/contact.. Directions to:.. UCONN.. UMB.. Contact Us.. Name.. Email.. Message.. *What is 2+2? (Anti-spam)..

    Original link path: /contact.php
    Open archive

  • Title: Bioarray - News
    Descriptive info: COMPANY.. TECHNOLOGY.. CONSULTING.. PUBLICATIONS.. DATA DOWNLOADS.. FTP.. Boston Business Journal, Nov 17, 2011:.. "Which startups are going with Gov.. Patrick to Brazil? (slideshow)".. Press Release.. MARCIA FOURNIER FOUNDER AND CEO OF BIOARRAY THERAPEUTICS TO JOIN GOVERNOR PATRICK ON INNOVATION ECONOMY MISSION TO BRAZIL.. Part of exciting opportunity to promote Massachusetts to new markets, create jobs.. BOSTON -- NOVEMBER, 16, 2011 – BIOARRAY’s Founder and CEO Marcia Fournier will join Massachusetts Governor Deval Patrick and a coalition of business executives, academic leaders and government officials on the.. Massachusetts.. -.. Brazil.. Innovation Economy Mission 2011.. this December to pursue job growth and economic development partnerships between Massachusetts and Brazil.. Marcia will contribute her expertise in cancer research and development of molecular diagnostics to help the delegation assess economic development opportunities that encourage Brazilian companies to invest and create jobs in Massachusetts.. During the trip, Marcia will take part in roundtables, company visits and meetings with government and business officials.. The Innovation Economy Mission to Brazil will enhance BIOARRAY’s position to carry out its mission of bringing molecular diagnostics to the clinic to help patients and doctors by improving breast cancer detection and treatments” said Marcia.. “As the Brazilian economy continues to grow, this opportunity will provide a forum to develop key collaborations with companies and universities, bring investments as well as boost exchange of scientific information and markets”.. “We are committed to competing for every job in every corner of the Commonwealth, and the world,” said Governor Patrick.. “To continue our recovery, we need to position Massachusetts for success in growing markets like Brazil, to drive job growth and catalyze international investment.. ” From  ...   for all subtypes of breast cancer and for multiple chemotherapy treatments.. Because doctors currently lack tools to identify which treatment will work best for a particular patient, BIOARRAY’s test can improve treatment decisions, eliminate chemotherapy treatments that have little or no therapeutic benefit, and significantly reduce treatment costs.. BIOARRAY’s team has developed an innovative tissue-based discovery approach that identifies better biomarkers and as a result, their test is more flexible and powerful than other tests under development.. For a young company, BIOARRAY has a strong, committed core team as well as an impressive scientific advisory board.. The company is a Silver Winner in this year’s 2011 MassChallenge competition, which had over 700 companies competing.. BIOARRAY has a rich pipeline of genomic products in development based on its unique biological approach and genomic platform.. BIOARRAY was founded in 2009 by scientists from the Dana-Farber Cancer Institute and Lawrence Berkeley National Laboratory and is based in Boston, Massachusetts.. About BIOARRAY’s CEO:.. Dr Fournier is trained in biology with 10+ years of experience in cancer research and a Founder and CEO of BIOARRAY Therapeutics.. In addition to BIOARRAY, she currently serves on multiple scientific committees for grant and peer-review journals as well as presenting in business innovation forums.. Dr Fournier most recently held a position at GlaxoSmithKline, Oncology Center of Excellence for Drug Discovery.. Dr Fournier’s work as a doctoral fellow at the Dana-Farber Institute and postdoctoral at Berkeley lead to seminal publications on biomarker discovery.. Fournier holds a Ph.. and a M.. in molecular biology from the Biophysics’ Institute at the Federal University of Rio de Janeiro, Brazil.. Technology.. Consulting.. Publications.. Data Downloads.. 2011..

    Original link path: /BIOARRAY%20Press%20Release%20Nov%2016,%202011.html
    Open archive

  • Title: Bioarray Our team
    Descriptive info: Board of directors.. Marcia Fournier, CEO.. I have been working for the last 10 years on questions related to how to detect and how to treat cancers.. I am currently building a biotechnology company, BIOARRAY Therapeutics Inc.. , with the mission of bringing new technologies to detect breast cancer at its very earliest stages and to predict optimal therapies.. BIOARRAY is formed to bring scientific success to patients.. Michal Preminger, Non-executive Chairman.. I joined Harvard OTD in 2005 following an earlier career in R&D and Markting/Business Development in the biotech and hi-tech industries.. Prior to joining Harvard, I held a number of business development and technology development positions at Compugen, most recently as Vice President of Protein Therapeutics, responsible for the business management of the company's emerging drug discovery pipeline.. Previously, I was involved in marketing and business development in the hi-tech industry, among others for Lucent Technologies.. I also co-founded Anima Cell Metrology, a biotechnology startup that targeted the development of real-time identification of proteins as they are synthesized in living cells.. My education started at the Hebrew University School of Medicine, where I, after deciding to move into science, earned an undergraduate degree in Medicine.. Following that, I got a masters degree and a PhD from the Weizmann Institute of Science, and an MBA from INSEAD in Fontainebleau, France.. In addition to my job at Harvard, I'm a member of the Board of Directors at Elminda (www.. elminda.. com) and BioArray Therapeutics (www.. bioarray.. us) and a member of the Scientific Advisory Board of Prize for Life (www.. prize4life.. org).. Specialties:Buidling Bridges: between science and business, early stage discoveries and technologies and their future commercial paths, academia and industry, and last, but not least, between people of different cultures, personalities, interests, motivations and perspectives.. Una S.. Ryan, Board Director.. Ryan is Managing Director Golden Seeds (Silicon Valley), an angel investing group focused on women-led companies.. She is also a member of Astia Angel, investing in women-led ventures while targeting above-market investment returns.. She has recently joined The Angel Forum, a group of 25 high net worth individuals, all of whom have been CEOs, founders of successful entrepreneurial ventures and who are now dedicated to investing in, mentoring and advising Silicon Valley Start ups.. She was previously President and CEO of Diagnostics For All (DFA), a non-profit organization developing inexpensive diagnostics for global health and agriculture.. She was also formerly President and CEO of AVANT Immunotherapeutics, Inc, (NASDAQ) a company developing vaccines and immunotherapeutics for cancer, travelers, food safety, and global health.. Ryan is also Research Professor of Medicine at BU School of Medicine.. Her board positions include AMRI (Lead Director, Nominating and Compensation committees) and MSH (Audit and Compensation committees).. She is a Board member of RenovoRx, a company developing an device that will enhance treatment options for pancreatic cancer patients and BioArray Therapeutics.. She was Chair of the Massachusetts Biotechnology Council, served on its Board (1996-2008), as well as the Biotechnology Industry Organization, New England Healthcare Institute, Board of Associates of the Whitehead Institute, Strategy & Policy Council of the MIT Center for Biomedical Innovation.. Ryan holds a Ph.. in Cellular and Molecular Biology from Cambridge University and BS degrees in Zoology, Microbiology and Chemistry from Bristol University.. She received an Honorary Doctor of Science degree form Bristol University in 2009.. In 2007, Dr.. Ryan received  ...   spent her career investing in novel products and companies through her roles in industry, on Wall Street and in venture capital.. She brings expert knowledge across all aspects of drug development and deals, an extensive Wall Street and industry network and experience in venture investing, corporate development and investor relations.. Specialties: Signifcant experience in the US and EU in venture investing, all aspects of M&A deals, Corporate Development, investor relations and corporate communications, and public market investing.. Judy Otto.. Judy has designed and delivered leadership and coaching programs for executive teams and individual high level managers.. As a former adjunct faculty member of The Center for Creative Leadership (CCL) at Rensselaer Learning Institute, she coached participants in CCL’s Leadership Development Program.. She served as adjunct faculty with Columbia University’s International Senior Executive Program, Boston University’s Executive Challenge Program, Antioch University, and Northeastern University.. She was an affiliate of Peter Block’s Designed Learning and Development Dimensions International.. A recent client survey cites Judy as "an exceptional coach.. ".. A high level of trust in Judy.. "she develops and sustains that trust with everyone she works with.. ".. Insight, compassion and resourcefulness: "she has an ability to identify and get to important and sensitive issues in a way that not only leaves people intact but actually affirms who they are.. She has consistently positive influence on individuals and groups – a transformative effect.. Openness, honesty/directness and integrity: "She speaks straight and speaks from the heart.. She is always in their corner, has a genuine respect for people.. There is clearly an integration between who she is as a person and what she does professionally.. Persistence: "She holds people accountable and doesn't let people "wiggle" away from tough issues.. gentle but persistent.. protects people’s self esteem but holds them accountable.. She knows how to bring out and maximize the best in people.. ”.. Learning and Growth: "She is open to feedback, current on what is going on in the field, and focused on her own growth and development.. Specialties:Judy works with her coaching clients in a holistic fashion, using a collaborative process.. The coaching is framed within a systems view of the client’s organization, taking into account the immediate and wider culture and environment.. As a former facilitator of Peter Block's Flawless Consulting, she employs that model: contracting, assessment, feedback with recommendations, and implementation.. Her work focuses on the client's self-awareness, followed by behavior change and skills building.. Board of scientific advisors.. Mina J.. Bissell.. http://.. lbl.. gov/LBL-Programs/lifesciences/BissellLab/main.. html.. Arthur B.. Pardee.. dfhcc.. harvard.. edu/membership/profile/member/1211/0/.. Stephen Blakemore.. com/profile/view?id=32957146&authType=name&authToken=7VmB&goback=.. Dean Oliver.. com/profile/view?id=160951&authType=name&authToken=Dn3H&goback=.. Co-founder.. Katherine J.. Martin Ph.. Martin has a PhD in Biochemistry from Brandeis University and was a fellow at Harvard University and the Dana-Farber Cancer Institute.. She held positions at biotech start-ups Amira Inc and Repligen Corp.. prior to funding BIOARRAY.. Dr Martin is an expert in multi-gene expression data analysis and biostatistics.. She is trained as a Molecular Biologist with 20 years of experience in the field of gene expression analysis, cancer biomarker discovery and cancer drug development.. She has published in key research publications the areas of mRNA markers for circulating tumor cells and breast cancer.. She has worked as an independent consultant with numerous scientists in industry and academia for the past 10 years to interpret a wide variety of genome-wide data, producing over 30 peer-reviewed scientific publications..

    Original link path: /ourteam.html
    Open archive

  • Title: Bioarray UCONN
    Descriptive info: View Larger Map.. Products..

    Original link path: /uconn.html
    Open archive

  • Title: Bioarray UMB
    Original link path: /umb.html
    (No additional info available in detailed archive for this subpage)

  • Title: Bioarray - Company
    Descriptive info: SCIENCE.. PRESS.. Executive Team.. Advisory Board.. BIOARRAY is located at:.. Technology Incubation Program.. University.. of Connecticut.. Cell and Genome Sciences Building.. Farmington, CT 06107.. is playing a role in the fight against breast cancer by bringing patients new molecular tests using genome-wide gene expression technology.. Our lead diagnostic will personalize breast cancer treatment by providing a patient and her doctor with the information needed to choose between multiple approved chemotherapy regimens.. We are an early-stage biotechnology company based in Boston and incorporated in 2009.. BIOARRAY is a Silver Winner at MassChallenge 2011..

    Original link path: /company.html
    Open archive

  • Title: Bioarray Technology
    Descriptive info: PRODUCTS.. Healthy breast cells form spherical and organized structures called acini.. Gene expression microarrays measures the activity of thousands human genes at once.. What is different about BIOARRAY’s technology?.. In contrast to pure statistical approaches, BIOARRAY discovers cancer markers by applying advanced mathematical approaches to the analysis of information about the normal cell organization process.. Using this biology-based approach, BIOARRAY identified unique RNA markers with very little overlap with other published RNA signatures.. We identified RNA markers representing key biological processes disrupted in breast cancer such as proliferation, migration, cell death, cell-cell interactions, and cell polarity.. BIOARRAY’s Healthy Cell organization Approach.. BIOARRAY’s tests.. are based on cancer markers (genes) discovered using a proprietary, patent-pending biology-based technology.. BIOARRAY's technology can be applied to multiple type of cancers including breast, prostate, colon and pancreatic cancers.. Abstract published at the Journal of Clinical Oncology as part of the 2011 Annual meeting of the American Society of Clinical Oncology (ASCO).. BIOARRAY reported positive results showing that its markers and algorithms stratified breast cancer patients by response (Fisher’s Exact p 0.. 05) to neoadjuvant (pre-surgery) treatment with taxane-based chemotherapy.. The studies evaluated the predictive value of 22 genes down regulated during the healthy organization process of breast epithelial cells in breast cancer  ...   treatment with paclitaxel, 5-fluorouracil, cyclophosphamide and doxorub-icin (T-FAC) followed by surgical resection.. Response was categorized as pathological complete response or residual disease.. The studies showed the performance of markers down-modulated during the healthy breast organization process to predict response to taxane-based chemotherapy T-FAC.. This study is the first example of a single gene signature to predict chemotherapy response in different molecular subtypes of breast cancer.. Its predictive value in ER-negative and basal-like breast cancers is notable.. Patients identified as non-responsive have the potential to benefit from adding an alternative treatment early in their care or from improved quality of life in forgoing an ineffective treatment.. Poster presentation at the 2010 Annual meeting of the American Society of Clinical Oncology (ASCO).. BIOARRAY reported analysis showing the identification of markers predictive of response to neoadjuvant (pre-surgery) chemotherapy with high accuracy.. ROC analysis values for sensitivity and specificity showed that BIOARRAY's predictive models were superior to clinical parameters alone.. These markers have the potential to fill the existing need for a diagnostic assay to provide accurate personalized information to guide decisions on chemotherapy treatment.. The study analyzed a preexisting microarray dataset (1 ) including samples from 133 breast cancer patients with stage I-III taken before treatment with neoadjuvant (pre-sugery) taxane-based chemotherapy..

    Original link path: /TECHNOLOGY.html
    Open archive


    Archived pages: 20